INIS
assessments
8%
balloons
7%
beams
12%
brachytherapy
42%
cancer
100%
carcinomas
33%
chemotherapy
6%
citrulline
7%
classification
5%
comparative evaluations
16%
concentration
5%
control
13%
data
11%
decision making
5%
diseases
18%
dose rates
7%
doses
20%
evaluation
7%
hazards
6%
hyperthermia
11%
images
15%
implants
9%
learning
9%
monitoring
5%
morbidity
6%
nmr imaging
10%
panels
7%
patients
77%
phantoms
7%
prediction
12%
prostate
20%
quality of life
13%
radiations
14%
radiotherapy
66%
rectum
15%
repair
6%
reviews
5%
risks
47%
space
6%
surgery
5%
symptoms
12%
therapy
13%
toxicity
17%
tumors
19%
verification
6%
volume
10%
women
13%
Keyphrases
Adjuvant Therapy
17%
Brachytherapy
15%
Cancer Treatment
6%
Cervical Cancer
8%
Cervical Carcinoma
8%
Chemoradiation
5%
Chemoradiotherapy
5%
Citrulline
5%
Combined Analysis
7%
Confidence Interval
5%
Endometrial Cancer
48%
Endometrial Carcinoma
17%
External Beam Radiotherapy
18%
HDR Brachytherapy
6%
Health-related Quality of Life
7%
High-risk Endometrial Cancer
7%
Hyperthermia
11%
Image-guided Brachytherapy
9%
Imaging Panel
6%
Integrated Risk
6%
Intermediate Risk
11%
Intraoperative Radiation Therapy
13%
Local Control
6%
Locally Advanced Cervical Cancer
16%
Lymphovascular Invasion
7%
Magnetic Resonance Imaging
5%
Mismatch Repair
6%
Molecular Profile
5%
Multimodal Deep Learning
6%
Overall Survival
8%
Pelvic Radiotherapy
5%
Pooled Analysis
5%
PORTEC
37%
Prostate
9%
Prostate Radiotherapy
7%
Quality of Life
5%
Radiation Therapy
16%
Radiotherapy
26%
Randomized Trial
9%
Rectum
7%
Recurrence Prediction
6%
Recurrence Risk
10%
Risk Assessment
5%
Risk Profile
6%
Small Intestine
5%
Treatment Verification
6%
Tumor
6%
Vaginal Brachytherapy
15%
Medicine and Dentistry
Adjuvant Therapy
17%
Adverse Event
6%
Brachytherapy
38%
Cancer Therapy
6%
Cervical Cancer
18%
Chemoradiotherapy
10%
Citrulline
6%
Disease
6%
DNA Mismatch Repair
6%
Endometrial Cancer
55%
Endometrium Carcinoma
22%
External Beam Radiotherapy
19%
High-Dose-Rate Brachytherapy
5%
Implant
8%
Magnetic Resonance Imaging
7%
Malignant Neoplasm
6%
Neoplasm
17%
Pelvic Radiotherapy
5%
Pelvis
12%
Prostate Cancer
7%
Protein P53
8%
Quality of Life
12%
Radiation Therapy
45%
Radiotherapy Prostate Cancer
5%
Recurrence Risk
8%
Recurrent Disease
13%
Symptom
14%
Uterine Cervix Carcinoma
9%
